Table 1. Association between patients’ demographics and drug susceptibility testing results.
| Variables | Drug resistance pattern | MDR | ||||
|---|---|---|---|---|---|---|
| Rifampicin (%) | Isoniazid (%) | Streptomycin (%) | Ethambutol (%) | Pyrazinamide (%) | ||
| Gender | ||||||
| Female | 127 (10.3) | 123 (9.9) | 35 (2.8) | 27 (2.2) | 19 (1.5) | 117 (9.5) |
| Male | 114 (10.1) | 110 (9.7) | 35 (3.1) | 38 (3.4) | 20 (1.8) | 104 (9.2) |
| P-value | 0.47 | 0.57 | 0.71 | 0.04 | 0.52 | 0.84 |
| Phi value | - | - | - | 0.05 | - | - |
| Age (years) | ||||||
| 10–25 | 110 (11.2) | 114 (11.6) | 32 (3.2) | 19 (1.9) | 13 (1.3) | 108 (11.0) |
| 26–45 | 84 (10.6) | 76 (9.7) | 20 (2.5) | 28 (3.5) | 16 (2) | 74 (9.4) |
| 46–65 | 39 (8.7) | 37 (8.3) | 13 (2.9) | 13 (2.9) | 9 (2) | 35 (7.8) |
| >65 | 8 (5.5) | 6 (4.1) | 5 (3.4) | 5 (3.4) | 1 (0.7) | 4 (2.8) |
| p-value | 0.12 | 0.06 | 0.83 | 0.37 | 0.68 | 0.008 |
| Phi value | - | - | - | - | - | 0.07 |
| TB treatment History | ||||||
| New patients | 74 (4.7) | 68 (4.3) | 30 (1.9) | 13 (0.8) | 15 (1) | 63 (4.0) |
| Previously treated patients | 167 (20.8) | 165 (20.6) | 40 (5) | 52 (6.5) | 24 (3) | 158 (19.7) |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Phi value | 0.25 | 0.26 | 0.08 | 0.16 | 0.07 | 0.255 |